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This issue is important because 
concerns about microheterogeneity 
have a long history. In the 1940s and 
early 1950s, proteins (and nucleic 
acids) were considered to be col-
loids that were unlikely to display 
the atomic and molecular precision 
of “real” molecules. This view, of 
course, began to dissipate with the 
Watson-Crick structure of DNA, the 
demonstration that at least some 
small proteins could be refolded into 
equilibrium conformations, and the 
finding that macromolecules could 
be crystallized and discrete struc-
tures obtained by X-ray diffraction. 
These developments appeared, at 
the time, to relegate earlier con-
cerns about microheterogeneity 
into the dustbin of scientific history. 
On the other hand, modern stud-
ies of protein and RNA folding and 
assembly suggest that there may 
be multiple pathways of folding and 
that individual proteins—and cer-
tainly individual macromolecular 
assemblies—could be trapped into 
metastable states with long-term 
stability. Learning more about such 
distributions of metastable states 
and their rates of rearrangement is 
of great intrinsic interest because 
this may tell us more about fold-
ing and assembly processes in vivo 
and in vitro and also about how far 
these processes are driven toward 
homogeneity by chaperone com-
plexes. In addition, such functional 
heterogeneity, if it exists, may pro-
vide further insight into regulatory 
events controlled by signal-trans-
duction networks because these 
regulatory processes could work 
somewhat differently on “outliers” 
within conformational distributions 
of macromolecular assemblies.
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A study by Zhang et al. (2006) in this issue of Cell provides compelling evidence that the 
tyrosine kinase domain of the epidermal growth factor receptor (EGFR) is activated by the 
formation of an asymmetric dimer, with one kinase domain in the EGF-mediated dimer 
activating the other through an allosteric mechanism.The receptor tyrosine kinase (RTK) 
family of cell-surface receptors 
includes the epidermal growth factor 
receptor (EGFR/ErbB1/HER1) and 
its relatives ErbB2/HER2, ErbB3/
HER3, and ErbB4/HER4. Receptors 
of the EGFR subgroup are essen-
tial for embryonic development 
and adult tissue homeostasis in 
both vertebrates and invertebrates. 
Enhanced signaling from these receptors, due to mutation or over-
expression, contributes to several 
types of human cancer (reviewed 
in Yarden and Sliwkowski, 2001). 
Like their RTK brethren, members 
of the EGFR subgroup feature an 
extracellular region (ectodomain) 
that binds polypeptide ligands 
(EGF, transforming growth factor-α, 
neuregulins, and several others), a 
single-pass transmembrane helix, Cell 125, Jand a cytoplasmic domain contain-
ing intrinsic tyrosine kinase activity 
(reviewed in Schlessinger, 2002).
RTK activation represents a sig-
nal transduction event in which an 
extracellular cue (such as a growth 
factor) is converted to a cellular 
response (for example, cell divi-
sion) through a series of intracel-
lular steps. The activation process 
for RTKs is simple yet complex. It une 16, 2006 ©2006 Elsevier Inc. 1029
appears simple because the fun-
damental mechanism is ligand-
induced receptor clustering. But it 
is complex due to the different lig-
and-receptor stoichiometries and 
the various mechanisms by which 
kinase activity is repressed in non-
activated receptors and stimulated 
in activated receptors (reviewed 
in Schlessinger, 2000; Hubbard, 
2004). In this issue of Cell, Zhang 
et al. (2006) provide evidence for an 
allosteric mechanism of kinase acti-
vation for the EGFR.
Several years ago, a wealth of 
structural data emerged on the ecto-
domain of EGFR and its relatives. 
These data revealed the molecular 
mechanisms by which the ectodo-
main is converted from a dimeriza-
tion-inhibited state to a dimeriza-1030 Cell 125, June 16, 2006 ©2006 Elsetion-competent state after binding 
of ligand (reviewed in Burgess et 
al., 2003). In structural terms, bind-
ing of EGF to its receptor facilitates 
formation of a symmetric EGF-
EGFR complex (with 2:2 stoichiom-
etry) on the extracellular side of the 
plasma membrane (Figure 1A). But 
what transpires on the cytoplasmic 
side of the plasma membrane? For 
most ligand-RTK complexes, lig-
and-mediated receptor dimerization 
is thought to position the two cyto-
plasmic tyrosine kinase domains 
for efficient trans-phosphorylation 
of tyrosine residues in the kinase 
activation loop, the juxtamem-
brane region (linking the transmem-
brane helix to the kinase domain), 
and elsewhere in the cytoplasmic 
domain. These phosphorylation 
figure 1. formation of an Active eGf-
eGfR Dimer
(A) On the extracellular side of the plasma 
membrane (shown approximately to scale), 
the EGF:EGFR complex (2:2 stoichiometry) is 
2-fold symmetric (the 2-fold axis is vertical). 
Depicted are the two receptors in the complex 
(cyan and purple) with the four subdomains (I–
IV) of the EGFR ectodomain and their bound 
EGF ligands (orange; E). The transmembrane 
helices are shown as cylinders, and linker seg-
ments including the juxtamembrane regions 
(extracellular and cytoplasmic) and C-terminal 
tail as lines. On the cytoplasmic side of the 
plasma membrane, the two tyrosine kinase 
domains (with N- and C-lobes) form an asym-
metric dimer, with the C-lobe (C) of one kinase 
domain (purple) interacting with the N-lobe (N) 
of the other kinase domain (cyan). This inter-
action activates the second kinase domain 
(cyan). Tyrosine phosphorylation sites in the 
C-terminal tail of the cytoplasmic domain 
are depicted as red spheres. The composite 
structure is derived from PDB codes 1VO and 
1NQL (ectodomain dimer) and from PDB code 
1M14 (cytoplasmic domain dimer).
(B) The mechanism of EGFR kinase activa-
tion: shown are the N-lobes and C-lobes of 
the EGFR kinase domains, the β sheet in the 
N-lobe containing Lys721 (orange; K), α helix 
C in the N-lobe containing Glu738 (green; E), 
and the activation loop in the C-lobe contain-
ing Leu834 (gray; L). The C-lobe of one kinase 
domain (purple) activates the second kinase 
domain (cyan) by interacting with α helix C, 
which facilitates formation of the Lys721-
Glu738 salt bridge (red dashed line) and prop-
er positioning for catalysis of the activation 
loop. In the absence of such an interaction 
(kinase colored purple), the activation loop 
is stabilized in a Src/CDK-like inactive state 
in which a short α helix in the activation loop 
(containing Leu834) and α helix C are stabi-
lized in an inactive configuration. The two ki-
nase domains are presumed to reverse roles 
in a dynamic fashion.vier Inc.events, particularly in the activation 
loop and juxtamembrane region, 
stabilize the catalytically competent 
state of the kinase (reviewed in Huse 
and Kuriyan, 2002; Hubbard, 2004). 
Phosphorylation sites also serve to 
recruit downstream signaling pro-
teins containing Src homology-2 
(SH2) or phosphotyrosine binding 
(PTB) domains. In contrast with 
most RTKs, all of the EGFR sites of 
tyrosine autophosphorylation, which 
recruit a host of signaling proteins, 
reside in a long flexible segment that 
is C-terminal to the kinase domain.
Despite containing a conserved 
tyrosine residue in the activation 
loop (Tyr845), phosphorylation of 
this tyrosine is not required for acti-
vation of the EGFR kinase. If not 
tyrosine phosphorylation, what then 
is the basis for activation of the EGFR 
kinase? Here is where the study by 
Zhang et al. (2006) weighs in. A pre-
vious crystal structure of the soluble 
EGFR kinase domain (which is mon-
omeric up to relatively high protein 
concentrations) showed the kinase 
to be in an active state (Stamos et al., 
2002), with the principal regulatory 
elements—the activation loop in the 
C-terminal kinase lobe (C-lobe) and 
α helix C in the N-terminal kinase 
lobe (N-lobe)—properly positioned 
for catalysis. This was consistent 
with the observation that phosphor-
ylation of the activation loop was not 
necessary for kinase activity, but it 
raised the question of why the EGFR 
kinase is not constitutively active. 
Zhang et al. (2006) went hunting for 
a crystal packing interaction that 
might resolve this conundrum. They 
asked whether there may exist in 
the crystal structure an interaction 
between two kinase domains that 
could explain why the crystallized 
kinase is in an active state, and, if 
so, whether this interaction might 
take place within the confines of a 
ligand-stabilized EGFR dimer.
The authors drew on their knowl-
edge of the structural intricacies of 
kinase activation in the nonreceptor 
tyrosine kinase Src and the serine/
threonine kinase cyclin-dependent 
kinase-2 (CDK2). They identified an 
intriguing crystal packing interac-
tion in the EGFR kinase structure 
in which the C-lobe of one EGFR 
kinase molecule makes contact with 
the N-lobe of a symmetry-related 
molecule. Notably, the symme-
try element that relates these two 
kinase molecules is a 3-fold screw 
axis, which means that this dimer 
is asymmetric rather than symmet-
ric (related by a 2-fold axis). In this 
asymmetric interaction, the C-lobe 
of one kinase “pushes” α helix C 
(N-lobe) of the other kinase toward 
the active site such that a critical 
lysine-glutamate (Lys721-Glu738) 
salt bridge can be made (Figure 1B). 
Although the molecular details differ, 
this interaction is highly reminiscent 
of the activation of CDK2 by binding 
of cyclinA (Jeffrey et al., 1995).
Structural insights gained from 
the preexisting EGFR kinase struc-
tures (Stamos et al., 2002; Wood 
et al., 2004), as well as from newly 
determined structures of their own, 
led Zhang et al. (2006) to propose 
that, following ligand-mediated 
dimerization of the EGFR, the two 
EGFR kinase domains form a cyclin/
CDK-like asymmetric dimer in which 
one kinase activates the other allos-
terically. From elegant biochemical 
studies of mutated forms of EGFR 
with an altered dimer interface, 
Zhang et al. (2006) provide strong 
support for this proposal. In addition, 
there is evolutionary data to support 
this mechanism. A sequence align-
ment of the four kinase domains of 
the EGFR subgroup shows that the 
C-lobe residues in the dimer inter-
face are conserved, that is, all four 
members are potential activators. In 
contrast, the relevant sequence in 
the N-lobe of the ErbB3 kinase, the 
one member of the subgroup that 
cannot be activated (due to substi-
tutions of key catalytic residues), 
is not conserved. This mechanism 
nicely explains how the catalytically 
inactive ErbB3 can still be an “active” 
participant in a heterodimeric com-
plex with one of the other members 
of the subgroup (Yarden and Sli-
wkowski, 2001).To get a picture of the basal (low 
activity) state of the EGFR kinase, 
Zhang et al. (2006) introduced a 
mutation (V924R) in the C-lobe of 
the EGFR kinase domain to pre-
vent formation of the asymmetric 
(activated) dimer. As predicted, the 
mutant kinase domain crystallizes in 
a different lattice, and the configura-
tion of the important regulatory ele-
ments (activation loop, α helix C) now 
resembles the inactive state of Src/
CDK (Figure 1B). A crystal structure 
of the EGFR kinase with an inhibitor 
bound (Wood et al., 2004) provided 
the first indication of this autoinhib-
ited state, but it was unclear whether 
the inhibitor induced this state. The 
structure of the V924R mutant thus 
supplies another important piece 
to the EGFR activation puzzle: in 
the monomeric state, the kinase 
domain of the EGFR is autoinhibited 
because the activation loop and α 
helix C, if not actually locked down 
in a Src/CDK-like inactive configura-
tion, can readily “sample” such an 
inactive configuration.
This structure of the monomeric, 
inactive state of the EGFR kinase 
also sheds light on an important clin-
ical finding. Recent studies of non-
small-cell lung cancer have shown 
that the small-molecule inhibitor 
gefitinib is highly efficacious for a 
subpopulation of patients who har-
bor particular mutations in the EGFR 
kinase domain (reviewed in Minna et 
al., 2004). These mutations are clus-
tered in the kinase activation loop, 
the nucleotide binding loop (N-
lobe), and the linker between the β 
sheet and α helix C. Although there 
has been some controversy as to 
whether these are kinase-activat-
ing mutations, the structure of the 
basal-state EGFR kinase (Zhang et 
al., 2006), along with accompanying 
biochemical data, indicates that the 
mutated residues (such as Leu834) 
are indeed important for maintaining 
basal-level catalytic activity (Figure 
1B). Moreover, because they desta-
bilize the inactive state of the kinase, 
these mutations render the kinase Cell 125, Jdomain vulnerable to gefitinib, which 
binds selectively to the active state. 
Although the wild-type EGFR (and 
other classes of mutants) becomes 
susceptible to gefitinib upon ligand-
induced dimerization, these particu-
lar kinase mutants are constitutive 
targets of the drug.
Several mechanistic issues per-
taining to EGFR activation remain 
outstanding, such as the extent to 
which EGFR exists as an inactive 
dimer on the cell surface, the struc-
tural nature of such a dimer, and 
the roles played by the transmem-
brane helix and C-terminal tail of 
the EGFR. Nevertheless, the Zhang 
et al. (2006) study fills some gaping 
holes in our knowledge of the regu-
latory mechanisms controlling this 
important subgroup of RTKs. It also 
reminds us that, although there is a 
natural inclination for us to seek out 
symmetry, biology has its own crite-
ria, and in some cases asymmetry 
will do just fine.
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